• Affimed NV (NASDAQ: AFMD) has announced initial clinical data from an investigator-sponsored study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE) AFM13 (CD16A/CD30).

• The trial evaluates the pre-complexing of AFM13 with cbNK cells followed by three weekly infusions of AFM13 monotherapy in adult patients with recurrent/refractory CD30-positive lymphomas.

• All four patients experienced significant disease reduction, with two complete responses and two partial responses as assessed by the investigator, with an objective response rate of 100%.

• There were no observed events of cytokine release syndrome, neurotoxicity syndrome, or graft-versus-host disease.

• The study is continuing enrollment of the second dose cohort.

• The company will host a conference call/webcast on April 14 at 4:05 p.m. E.T.

• Price Action: AFMD shares rise 40.8% at $11.05 in the premarket session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Affimed To Study AFM24/SNK-01 Combo In Solid Tumor Settings

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.